Stocks and Investing
Stocks and Investing
Fri, April 25, 2014
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, April 24, 2014
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Christopher Marai Maintained (BIIB) at Strong Buy with Increased Target to $415 on, Apr 24th, 2014
Christopher Marai of Nomura, Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $413 to $415 on, Apr 24th, 2014.
Christopher has made no other calls on BIIB in the last 4 months.
There are 3 other peers that have a rating on BIIB. Out of the 3 peers that are also analyzing BIIB, 0 agree with Christopher's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Christopher
- Matthew Harrison of "Morgan Stanley" Initiated at Buy and Held Target at $395 on, Thursday, March 27th, 2014
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $400 on, Friday, February 14th, 2014
- Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $415 on, Tuesday, January 28th, 2014